Indivior (INDV) Reaches New 1-Year High at $480.50

Indivior PLC (LON:INDV) shares reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as GBX 480.50 ($6.45) and last traded at GBX 478.60 ($6.42), with a volume of 1077371 shares. The stock had previously closed at GBX 467.20 ($6.27).

A number of research firms have recently weighed in on INDV. Numis Securities reiterated a “buy” rating and issued a GBX 600 ($8.05) price objective on shares of Indivior in a research note on Wednesday, May 2nd. Jefferies Group increased their price objective on shares of Indivior from GBX 610 ($8.18) to GBX 630 ($8.45) and gave the stock a “buy” rating in a research note on Tuesday, May 8th. Citigroup lowered shares of Indivior to a “neutral” rating and increased their price objective for the stock from GBX 490 ($6.57) to GBX 500 ($6.71) in a research note on Tuesday, May 15th. Morgan Stanley increased their price objective on shares of Indivior from GBX 450 ($6.04) to GBX 455 ($6.10) and gave the stock an “equal weight” rating in a research note on Tuesday, April 3rd. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a GBX 540 ($7.25) price objective on shares of Indivior in a research note on Friday, March 23rd. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of GBX 520.83 ($6.99).

In related news, insider Shaun Thaxter sold 551,896 shares of the firm’s stock in a transaction on Monday, March 12th. The shares were sold at an average price of GBX 404 ($5.42), for a total transaction of £2,229,659.84 ($2,991,627.32).

Indivior Company Profile

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply